GlassScriptPhysician profile
Karuna S Koneru
NPI 1336146372
$1,284.62
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.51 · 2020: $28.69 · 2021: $30.93 · 2022: $84.74 · 2023: $595 · 2024: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $227.77 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $141.06 | 2020-2023 | Lynparza |
| Merck Sharp & Dohme LLC | $132.75 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $108.79 | 2024 | Enhertu |
| Beigene USA, INC. | $97.42 | 2024 | Brukinsa |
| Genzyme Corporation | $91.75 | 2023-2024 | |
| Celgene Corporation | $72.59 | 2022-2023 | Reblozyl, Pomalyst |
| Eisai INC. | $62.77 | 2023-2024 | |
| Pfizer INC. | $50.68 | 2023 | |
| Glaxosmithkline, LLC. | $42.47 | 2023 | Zejula |
| Regeneron Healthcare Solutions, INC. | $36.39 | 2023 | Libtayo |
| Exelixis INC. | $35.91 | 2022-2023 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $32.38 | 2023 | Opdivo, Opdualag |
| Genentech USA, INC. | $30.47 | 2019-2023 | Gavreto, Tecentriq, Rozlytrek |
| Abbvie INC. | $29.25 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27.53 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $19.55 | 2023 | Ultomiris |
| Genmab U.S., INC. | $19.54 | 2024 | Epkinly |
| Janssen Biotech, INC. | $14.08 | 2019 | |
| Amgen INC. | $11.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karuna Koneru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.